Y-mabs announces second quarter 2024 conference call and webcast

New york, aug. 05, 2024 (globe newswire) -- y-mabs therapeutics, inc. (the “company” or “y-mabs”) (nasdaq: ymab), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report second quarter 2024 financial and operating results before market open on monday, august 12, 2024. the company will hold a conference call and webcast to discuss these results at 8:00 a.m. et.
YMAB Ratings Summary
YMAB Quant Ranking